October 4, 2018
Authored and Edited by Megan L. Meyers; Thomas L. Irving
On September 24, 2018, FDA issued final guidance on ANDA Submissions – Content and Format. The guidance outlines recommendations for the information that should be provided in each section of the common technical document (CTD) for human pharmaceutical product applications and identifies supporting guidance documents and recommendations issued by FDA to assist applicants in preparing their ANDA submission. The guidance seeks to assist ANDA applicants in improving the quality of their submissions, to increase the number of original ANDAs acknowledged for receipt upon initial submission, and to decrease the number of ANDA review cycles.
The CTD consists of five modules: Administrative Information and Prescribing Information, Summaries, Quality, Nonclinical, and Clinical. This guidance provides additional detail about the information that should be submitted in the applicable modules, sections, and subsections. Each regulatory authority that accepts the CTD uses its own Module 1, while Modules 2 through 5 are common for all regions.
FDA recommends the Summaries module include a Quality Overall Summary section, which provides an overview of the chemistry, manufacturing, and controls (CMC) section of the application and summarizes information about the drug substance (i.e., the API) and the drug product. This module should also include a Clinical Summary section, which contains summary data critical to the determination of bioequivalence (BE). The Quality module should contain all the CMC information necessary to support the application, including information supporting and verifying what was set forth in the Summaries section. This includes information, such as regional information, related to the drug substance and drug product. Regarding the Nonclinical module, this guidance suggests that ANDAs do not generally contain data typically included in this module, but if nonclinical study reports or safety assessments are submitted in support of a proposed specification, they should be included. Finally, FDA recommends the Clinical module contain all the clinical study report data needed to support the application and to demonstrate that the generic drug product is BE to the reference listed drug (RLD).
Readers are encouraged to read the final guidance, also available on FDA’s website.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
April 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.